LV13089B - 4-oxo-and 4h-imidazo(5,1-c)(1,4)benzoxazines useful as benzodiazepine receptor-binding agents - Google Patents

4-oxo-and 4h-imidazo(5,1-c)(1,4)benzoxazines useful as benzodiazepine receptor-binding agents Download PDF

Info

Publication number: LV13089B
Authority: LV; Latvia
Prior art keywords: alkyl; imidazo; aryl; fluoro; compound
Prior art date: 1992-02-13

Application number

LVP-03-63A

Other languages

English (en)

Latvian (lv)

Inventor

Sharon N Bisaha

Ronald B Gammill

Original Assignee

Upjohn Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-02-13

Filing date

2003-06-12

Publication date

2004-01-20

2003-06-12 Application filed by Upjohn Co filed Critical Upjohn Co

2004-01-20 Publication of LV13089B publication Critical patent/LV13089B/en

Links

102000004300 GABA-A Receptors Human genes 0.000 title claims description 7
108090000839 GABA-A Receptors Proteins 0.000 title claims description 7
FYGZDVOIYMRCOZ-UHFFFAOYSA-N 4h-imidazo[5,1-c][1,4]benzoxazine Chemical class C1OC2=CC=CC=C2N2C1=CN=C2 FYGZDVOIYMRCOZ-UHFFFAOYSA-N 0.000 title description 2
239000011230 binding agent Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 46
150000003839 salts Chemical class 0.000 claims abstract description 12
-1 -CH 2 CH 2 CF 3 Chemical group 0.000 claims description 48
125000000217 alkyl group Chemical group 0.000 claims description 26
125000003118 aryl group Chemical group 0.000 claims description 22
229910052739 hydrogen Inorganic materials 0.000 claims description 9
229910052801 chlorine Inorganic materials 0.000 claims description 7
229910052731 fluorine Inorganic materials 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
229910052794 bromium Inorganic materials 0.000 claims description 6
229910052757 nitrogen Inorganic materials 0.000 claims description 6
208000015114 central nervous system disease Diseases 0.000 claims description 5
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
125000005842 heteroatom Chemical group 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
239000011593 sulfur Substances 0.000 claims description 4
210000003169 central nervous system Anatomy 0.000 claims description 3
125000004122 cyclic group Chemical group 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
229910052740 iodine Inorganic materials 0.000 claims description 3
125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
OEZMZWGWHYOSGL-UHFFFAOYSA-N 2h-1,4-benzoxazine-3-carboxylic acid Chemical compound C1=CC=C2OCC(C(=O)O)=NC2=C1 OEZMZWGWHYOSGL-UHFFFAOYSA-N 0.000 claims 1
QRICQLNFDLNWPD-UHFFFAOYSA-N 5-cyclopropyl-1,2,4-oxadiazole Chemical compound C1CC1C1=NC=NO1 QRICQLNFDLNWPD-UHFFFAOYSA-N 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
AXDSXKHGEBSOHB-UHFFFAOYSA-N tert-butyl 6-cyano-7-fluoro-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxylate Chemical compound C1=CC(F)=C(C#N)C2=C1N1C=NC(C(=O)OC(C)(C)C)=C1CO2 AXDSXKHGEBSOHB-UHFFFAOYSA-N 0.000 claims 1
UCCWJUWUHMVASJ-UHFFFAOYSA-N imidazo[4,5-h][1,2]benzoxazine Chemical class C1=CC2=CC=NOC2=C2C1=NC=N2 UCCWJUWUHMVASJ-UHFFFAOYSA-N 0.000 abstract description 12
230000000147 hypnotic effect Effects 0.000 abstract description 4
230000000949 anxiolytic effect Effects 0.000 abstract description 3
239000002249 anxiolytic agent Substances 0.000 abstract description 2
229940005530 anxiolytics Drugs 0.000 abstract description 2
239000003326 hypnotic agent Substances 0.000 abstract description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
238000000034 method Methods 0.000 description 14
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
238000003756 stirring Methods 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 8
239000000243 solution Substances 0.000 description 7
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
235000019439 ethyl acetate Nutrition 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
125000004432 carbon atom Chemical group C* 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
ZKNRUFWEZPGGQP-UHFFFAOYSA-N 6-fluoro-4h-1,4-benzoxazin-3-one Chemical compound O1CC(=O)NC2=CC(F)=CC=C21 ZKNRUFWEZPGGQP-UHFFFAOYSA-N 0.000 description 4
239000012043 crude product Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000012530 fluid Substances 0.000 description 4
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
239000012267 brine Substances 0.000 description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000001035 drying Methods 0.000 description 3
IBRVAJQHFYKYKA-UHFFFAOYSA-N ethyl 7-fluoro-4h-imidazo[5,1-c][1,4]benzoxazine-3-carboxylate Chemical compound FC1=CC=C2N3C=NC(C(=O)OCC)=C3COC2=C1 IBRVAJQHFYKYKA-UHFFFAOYSA-N 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
238000011049 filling Methods 0.000 description 3
125000001072 heteroaryl group Chemical group 0.000 description 3
239000012948 isocyanate Substances 0.000 description 3
150000002513 isocyanates Chemical class 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
239000012044 organic layer Substances 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 2
PVTXJGJDOHYFOX-UHFFFAOYSA-N 2h-1,4-benzoxazine Chemical compound C1=CC=C2N=CCOC2=C1 PVTXJGJDOHYFOX-UHFFFAOYSA-N 0.000 description 2
QRCGFTXRXYMJOS-UHFFFAOYSA-N 4h-1,4-benzoxazin-3-one Chemical compound C1=CC=C2NC(=O)COC2=C1 QRCGFTXRXYMJOS-UHFFFAOYSA-N 0.000 description 2
241000220479 Acacia Species 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000008135 aqueous vehicle Substances 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
229960002200 flunitrazepam Drugs 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000008024 pharmaceutical diluent Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
239000000932 sedative agent Substances 0.000 description 2
230000001624 sedative effect Effects 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 description 1
125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
125000004515 1,2,4-thiadiazol-3-yl group Chemical group S1N=C(N=C1)* 0.000 description 1
125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 description 1
125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 1
125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
125000001414 1,2,4-triazol-5-yl group Chemical group [H]N1N=C([H])N=C1[*] 0.000 description 1
125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical class N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 description 1
HDXORWFRWVOYLO-UHFFFAOYSA-N 2,4-dihydroimidazo[5,1-c][1,4]benzoxazin-1-one Chemical class C1=CC=C2N3C(=O)NC=C3COC2=C1 HDXORWFRWVOYLO-UHFFFAOYSA-N 0.000 description 1
125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
MGOLNIXAPIAKFM-UHFFFAOYSA-N 2-isocyanato-2-methylpropane Chemical compound CC(C)(C)N=C=O MGOLNIXAPIAKFM-UHFFFAOYSA-N 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
RVMNXEUFMRISAT-UHFFFAOYSA-N 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4h-imidazo[5,1-c][1,4]benzoxazine Chemical compound C=1C(F)=CC=C(N2C=N3)C=1OCC2=C3C(N=1)=NOC=1C1CC1 RVMNXEUFMRISAT-UHFFFAOYSA-N 0.000 description 1
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
HTVDLCBBFHHYPN-UHFFFAOYSA-N 5-cyclopropyl-3-isocyanato-1,2,4-oxadiazole Chemical compound O=C=NC1=NOC(C2CC2)=N1 HTVDLCBBFHHYPN-UHFFFAOYSA-N 0.000 description 1
CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
DQRFDTSIKCECRD-UHFFFAOYSA-N 6-fluoro-3-oxo-4h-1,4-benzoxazine-5-carbonitrile Chemical compound O1CC(=O)NC2=C(C#N)C(F)=CC=C21 DQRFDTSIKCECRD-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
239000000538 analytical sample Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
150000005130 benzoxazines Chemical class 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
238000001816 cooling Methods 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000011737 fluorine Chemical group 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
WGYMXASRWCYKQR-UHFFFAOYSA-N imidazo[1,5-a]quinoxaline Chemical compound C1=CC=C2N3C=NC=C3C=NC2=C1 WGYMXASRWCYKQR-UHFFFAOYSA-N 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000002664 nootropic agent Substances 0.000 description 1
230000001777 nootropic effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000004866 oxadiazoles Chemical class 0.000 description 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Adhesives Or Adhesive Processes (AREA)

LVP-03-63A 1992-02-13 2003-06-12 4-oxo-and 4h-imidazo(5,1-c)(1,4)benzoxazines useful as benzodiazepine receptor-binding agents LV13089B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US83664592A	1992-02-13	1992-02-13

Publications (1)

Publication Number	Publication Date
LV13089B true LV13089B (en)	2004-01-20

Family

ID=25272407

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-03-63A LV13089B (en)	1992-02-13	2003-06-12	4-oxo-and 4h-imidazo(5,1-c)(1,4)benzoxazines useful as benzodiazepine receptor-binding agents

Country Status (11)

Country	Link
US (1)	US5610158A (de)
EP (1)	EP0625982B1 (de)
JP (1)	JP3512110B2 (de)
AT (1)	ATE219083T1 (de)
AU (1)	AU3443593A (de)
DE (1)	DE69332019T2 (de)
DK (1)	DK0625982T3 (de)
ES (1)	ES2177539T3 (de)
LV (1)	LV13089B (de)
PT (1)	PT625982E (de)
WO (1)	WO1993016082A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9410469D0 (en) *	1994-05-25	1994-07-13	Erba Farmitalia	Imidazolylalkyl derivatives of imidazo (5,1-c) (1,4) benzoxazin-1-one and process for their preparation
ZA968661B (en) *	1995-11-17	1998-04-14	Upjohn Co	Oxazolidinone antibacterial agent with tricyclic substituents.
JP2009523820A (ja) *	2006-01-23	2009-06-25	アミラファーマシューティカルス，インコーポレーテッド	５−リポキシゲナーゼの三環系抑制剤
CU20090172A6 (es)	2009-10-09	2011-10-05	Facultad De Quimica Universidad De La Habana	Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular
TWI674262B (zh)	2011-01-10	2019-10-11	美商英菲尼提製藥股份有限公司	製備異喹啉酮之方法及異喹啉酮之固體形式
JP6523267B2 (ja) *	2013-06-24	2019-05-29	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	Ｆｓｈｒの調節剤としてのイミダゾール化合物及びその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1052009B (it) *	1975-12-30	1981-06-20	Erba Carlo Spa	Imidazo 4.3 c 1.4 benzossazino imidazo 4.3 c 1.4 benzotiazino pirazo 2.1 c 1.4 benzossazino e pirazo 2.1 c 1.4 benzotiazino derivati
GB2043637B (en) *	1979-02-09	1983-03-16	Roussel Lab Ltd	Heterotricyclic derivatives
DK476885D0 (da) *	1985-10-17	1985-10-17	Ferrosan As	Heterocycliske forbindelser og fremgangsmaader til fremstilling heraf
DK155524C (da) *	1987-03-18	1989-09-11	Ferrosan As	Kondenserede imidazolderivater og farmaceutiske praeparater indeholdende disse
DK160876C (da) *	1987-12-08	1991-10-14	Novo Nordisk As	Imidazoquinoxalinforbindelser, fremgangsmaade til deres fremstilling, anvendelse af forbindelserne og farmaceutiske praeparater, hvori forbindelserne indgaar

1993
- 1993-01-14 JP JP51405293A patent/JP3512110B2/ja not_active Expired - Fee Related
- 1993-01-14 EP EP93902972A patent/EP0625982B1/de not_active Expired - Lifetime
- 1993-01-14 AT AT93902972T patent/ATE219083T1/de not_active IP Right Cessation
- 1993-01-14 DK DK93902972T patent/DK0625982T3/da active
- 1993-01-14 ES ES93902972T patent/ES2177539T3/es not_active Expired - Lifetime
- 1993-01-14 WO PCT/US1993/000095 patent/WO1993016082A1/en not_active Ceased
- 1993-01-14 PT PT93902972T patent/PT625982E/pt unknown
- 1993-01-14 AU AU34435/93A patent/AU3443593A/en not_active Abandoned
- 1993-01-14 DE DE69332019T patent/DE69332019T2/de not_active Expired - Fee Related
1994
- 1994-08-03 US US08/285,560 patent/US5610158A/en not_active Expired - Fee Related
2003
- 2003-06-12 LV LVP-03-63A patent/LV13089B/en unknown

Also Published As

Publication number	Publication date
PT625982E (pt)	2002-10-31
WO1993016082A1 (en)	1993-08-19
DE69332019T2 (de)	2002-11-28
AU3443593A (en)	1993-09-03
US5610158A (en)	1997-03-11
DK0625982T3 (da)	2002-09-30
JPH07503727A (ja)	1995-04-20
DE69332019D1 (de)	2002-07-18
JP3512110B2 (ja)	2004-03-29
ATE219083T1 (de)	2002-06-15
EP0625982B1 (de)	2002-06-12
EP0625982A1 (de)	1994-11-30
ES2177539T3 (es)	2002-12-16

Publication	Publication Date	Title
CN111153901B (zh)	2022-01-25	一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
AU2019392231B2 (en)	2022-10-20	Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound
KR20240136407A (ko)	2024-09-13	벤조피리미딘 화합물 및 이의 용도
DE69519666T2 (de)	2001-04-26	Durch einen pyridinring substituierte thiazolidine und oxazolidine und ihre anwendung als hypoglykämische mittel
DE60219672T2 (de)	2007-12-27	Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften
AU2006206654A1 (en)	2006-07-27	Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of Alzheimer's disease
AU2015252654A1 (en)	2016-11-03	Polyfluorinated compounds acting as Bruton's tyrosine kinase inhibitors
CN107949562A (zh)	2018-04-20	毒蕈碱性m2受体的正性变构调节剂
KR20130046436A (ko)	2013-05-07	안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n''-다이아릴티오우레아 및 n,n''-다이아릴우레아, 이의 제조방법 및 이의 용도
CN115427035A (zh)	2022-12-02	Enl/af9 yeats抑制剂
CN118632850A (zh)	2024-09-10	Apol1的螺环抑制剂和其使用方法
CA3037692A1 (en)	2018-03-29	Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
CA3018602C (en)	2021-06-22	Pyrimidin-4-yl imidazolidine-2-one derivatives and compositions having mutant idh inhibitory activity, preparation method and use thereof
JP7840327B2 (ja)	2026-04-03	新規インダゾールアセチレン誘導体
LV13089B (en)	2004-01-20	4-oxo-and 4h-imidazo(5,1-c)(1,4)benzoxazines useful as benzodiazepine receptor-binding agents
CN114516832A (zh)	2022-05-20	一种微管蛋白抑制剂及其制备方法与应用
JP2025537873A (ja)	2025-11-20	Ｍｃ４ｒ拮抗剤化合物、薬物組成物及びその医薬における使用
CN114599655B (zh)	2024-02-27	咪唑烷酮类化合物及其制备方法与应用
CN118108704A (zh)	2024-05-31	Kif18a抑制剂
KR20240051146A (ko)	2024-04-19	방향족 헤테로고리 화합물, 이를 함유한 약물 조성물 및 이의 응용
KR102493756B1 (ko)	2023-01-31	신규 5-옥소-1,2,4-옥사다이아졸 유도체, 이의 제조방법 및 이의 용도
CN120265641A (zh)	2025-07-04	GHSR 1a激动剂、药物组合物及其制备方法和应用
WO2024083980A1 (en)	2024-04-25	Bicyclic ferroportin inhibitors
CN120817958A (zh)	2025-10-21	苯并呋喃类化合物及其制备方法和应用
WO2024020350A1 (en)	2024-01-25	Tead inhibitors and methods of use